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Abstract
Perinatal hypoxic ischemia (H-I) causes brain damage and long-term neurological impairments, leading to motor
dysfunctions and cerebral palsy. Many studies have demonstrated that the TrkB-ERK1/2 signaling pathway plays a key role
in mediating the protective effect of brain-derived neurotrophic factor (BDNF) following perinatal H-I brain injury in
experimental animals. In the present study, we explored the neuroprotective effects of the TrkB-specific agonist monoclonal
antibody 29D7 on H-I brain injury in neonatal rats. First, we found that intracerebroventricular (icv) administration of 29D7 in
normal P7 rats markedly increased the levels of phosphorylated ERK1/2 and phosphorylated AKT in neurons up to 24 h.
Second, P7 rats received icv administration of 29D7 and subjected to H-I injury induced by unilateral carotid artery ligation
and exposure to hypoxia (8% oxygen). We found that 29D7, to a similar extent to BDNF, significantly inhibited activation of
caspase-3, a biochemical hallmark of apoptosis, following H-I injury. Third, we found that this 29D7-mediated
neuroprotective action persisted at least up to 5 weeks post-H-I injury as assessed by brain tissue loss, implicating long-
term neurotrophic effects rather than an acute delay of cell death. Moreover, the long-term neuroprotective effect of 29D7
was tightly correlated with sensorimotor functional recovery as assessed by a tape-removal test, while 29D7 did not
significantly improve rotarod performance. Taken together, these findings demonstrate that pretreatment with the TrkB-
selective agonist 29D7 significantly increases neuronal survival and behavioral recovery following neonatal hypoxic-
ischemic brain injury.
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Introduction
Ischemic brain injury is a major cause of neurological
impairments and mortality in adults and childhood, leading to
severe cognitive and motor dysfunctions upon survival. Several key
molecular and cellular processes responsible for ischemia-induced
neuronal death have been identified in mature and developing
brains, among which are glutamate and nitric oxide neurotoxicity,
calcium accumulation, caspase activation and inflammatory
activation [1,2,3,4,5]. Extensive biochemical and histochemical
analyses have detected evidence for necrosis, apoptosis following
ischemic injury [6,7,8,9,10,11], suggesting a heterogeneous
phenotypic nature of cell death. Currently there are no clinically
effective treatments that provide robust neuroprotection and/or
recovery.
Neurotrophins (NTs) are large secreted peptides that play
important roles in neuronal survival, differentiation, and synaptic
plasticity. Brain-derived neurotrophic factor (BDNF), the endog-
enous agonist for the tropomyosin-related kinase B (TrkB), has
been shown to exert strong survival and neuroprotective effects in
the central nervous system (CNS) and to facilitate post-injury
recovery and activity-dependent synaptic plasticity
[12,13,14,15,16]. BDNF binding to TrkB induces subsequent
activation of downstream signaling cascades (the ERK1/2 and
AKT pathways) responsible for cell survival. For example, in the
primary neuronal cultures, BDNF protected hippocampal neurons
against glutamate toxicity and glucose deprivation [17,18] and
rescued cerebellar granular neurons from apoptotic stimuli
[19,20]. This neurotrophic factor prevented neuronal cell death
in vivo when given by infusion or virus-mediated delivery
[21,22,23,24], and attenuated behavioral deficits following spinal
cord injury and ischemic stroke [25,26,27,28]. Moreover, BDNF
administration after spinal root avulsion prevented death of motor
neurons, reversed cholinergic enzyme deficiency and induced
axonal outgrowth of severely damaged axon terminals [29].
Despite these promising observations, however, BDNF failed to
show any efficacy in clinical outcome measures in patients with
amyotrophic lateral sclerosis [30,31]. There are multiple factors
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that limit utilization of BDNF as a practical therapeutic reagent,
including its poor bioavailability and short plasma half-life, and a
lack of specificity for NT receptors. The latter is important in
regard to the fact that BDNF also binds to the low-affinity p75
neurotrophin receptor (p75NTR), activation of which is respon-
sible for neuronal cell death in many experimental settings
[26,32,33]. Given these opposite effects of activation of TrkB and
p75NTR on neurons, the molecular intervention for the specific
activation of TrkB receptor, but not p75NTR, is desired to protect
neuronal injury.
It has been reported that a novel TrkB-selective monoclonal
antibody, 29D7, binds the extracellular domain of TrkB (but not
p75NTR), activates its downstream signaling pathways, and
promotes neuronal survival and neurite outgrowth in rodent
primary neuronal cultures [34]. We, therefore, utilized this TrkB-
selective antibody to explore its neuroprotective action in a
neonatal model of hypoxic-ischemic brain injury. A rodent model
of neonatal H-I initially described by Rice et al. [35] has been
widely used to study the pathophysiology and therapeutic
approaches implicated in neonatal H-I brain injury, a major
contributor to newborn infant death and long-term neurological
abnormalities. We have previously reported that BDNF treatment
protects the brain against H-I-induced injury in neonatal rats
[4,36]. Using this model, we demonstrate here that the TrkB
agonist antibody 29D7 activated the key TrkB downstream
cascades (ERK1/2 and AKT), significantly reduced brain damage




The TrkB-selective monoclonal antibody 29D7 and isotype-
matching control IgG were generated as previously described [34]
and provided by Wyeth Research. Recombinant human BDNF
was purchased from Peprotech (Rocky Hill, NJ).
Animals and the Surgical Procedure
All experimental protocols were approved by the Animal
Studies Committee at Seoul National University. All surgery was
performed under isoflurane anesthesia and all efforts were made to
minimize suffering. Newborn Sprague-Dawley rats (both genders)
were obtained from Samtako (Gyung-gi, Korea) when the pups
were 3–4 days of age. Pups were housed with their dam in home
cages under a 12/12 h light/dark cycle, with food and water freely
available throughout the study. The neonatal H-I brain injury
model was performed as previously described [35,36,37,38] with
modifications. At post-natal day 7 (P7), rats were anesthetized with
2.5% isoflurane and the left common carotid artery was
permanently ligated. The incision was sutured and the pups were
returned to the mother for a 2 h recovery and feeding period. Pups
were then placed in a humidified hypoxic chamber with 8%
oxygen (balance nitrogen) flow at 37uC for 2.5 h. Following H-I
injury, pups were returned to their cages and remained with their
mother.
Experimental Groups
The first set of experiments was performed to assess whether
29D7 induces activation of ERK1/2 and AKT in control (no H-I
surgery) P7 rats. Two groups of rats were used: 1) control IgG,
0.3 nmol (n=10) and 2) 29D7, 0.3 nmol (n=50). At various time
points indicated in Fig. 1 after the injection, cortical brain samples
(n=5 per time point) were prepared for Western blot and
immunohistochemical analyses. The second set of experiments
was designed to examine the effect of the TrkB agonist on
apoptosis in the brain 24 h following H-I. Three groups of P7 rats
were used: 1) IgG (n=12), 2) BDNF (n=10), and 3) 29D7 (n=12).
The third set of experiments was designed to determine the effect
of 29D7 on brain tissue loss 7 days following H-I. Three groups of
rats were used: 1) control IgG (n=25), 29D7, 0.1 nmol (n=15),
and 29D7, 0.3 nmol (n=15). The fourth set of experiments was
designed to assess the effect of 29D7 on body temperature. Three
groups of P7 rats were used: 1) sham surgery control (n=6), 2) H-
I:IgG (n=7) and 3) H-I:29D7 (n=7). The fifth set of experiments
was designed to examine long-term behavioral outcome and brain
tissue loss following H-I. Three groups of rats were used: 1) sham
surgery:IgG (n=6), 2) H-I:IgG (n=13), and 3) H-I:29D7 (n=13).
We found that mortality was not significantly different between
IgG- and 29D7-treated groups when assessed 24 h post H-I (IgG:
11.8% vs. 29D7: 12.2%, P.0.05). All assessments were performed
by investigators blinded to the surgical procedure and treatments.
Intracerebroventricular (icv) Administration
For drug treatments, pups received icv administration of BDNF,
29D7, or isotype-matching control antibody (IgG) just prior to
hypoxic injury into the left ventricle ipsilateral to H-I injury per
our published protocol [36,39]. Under isoflurane anesthesia, rats
were subjected to icv injection (2 mm rostral to bregma, 1.5 mm
lateral, and 2 mm deep to the skull surface) in a volume of 5 ml
using a Hamilton syringe with a 27 gauge needle.
Measurement of Body Temperature
Body temperature was monitored using a digital infrared ear
thermometer (Black & Decker, Pasadena, CA). Body temperature
was firstly recorded and animals immediately received an icv
administration of 29D7 or control IgG followed by exposure to
hypoxia for 2.5 h. The second measurement of body temperature
was performed after completion of hypoxia.Pups were then
returned to their dam andbody temperature was measured up to
7 days post-H-I.
Western Blot Analysis
Brain tissues from the cortex were dissected and frozen in dry
ice. Tissue samples were homogenized in a lysis buffer (10 mM
HEPES, pH 7.4, 5 mMMgCl2, 1 mM dithiothreitol, 1% Triton X-
100, 2 mM EGTA, 2 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride and Protease Inhibitor Cocktail) and centrifuged at
12,0006g for 10 min at 4uC. Proteins (30 mg/lane) were separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes (Bio-Rad Laboratories,
Hercules, CA, USA) as previously described [4,36]. Blots were
blocked with 3% dried milk in Tris-buffered saline containing
0.05% Tween 20 at 25uC for 2 h. Blots were then incubated with
primary antibodies, followed by incubation with anti-rabbit or
anti-mouse horseradish peroxidase-conjugated IgG and visualized
with enhanced chemiluminescence (LabFrontier, Seoul, Korea).
Primary antibodies used were as follows: rabbit anti-caspase 3
(1:1000, Cell Signaling Technology, Danvers, MA); rabbit anti-a-
spectrin (1:2000, Chemicon, Temecula, CA); anti-b-actin (1:3000);
and anti-poly(ADP-ribose) polymerase (PARP) (1:1000, Santa
Cruz Biotechnology, Santa Cruz, CA), and anti-phospho-ERK1/
2 (1:1000), anti-phospho-AKT (1:1000), anti-total EKK1/2
(1:2000) and anti-total AKT (1:2000) antibodies from Cell
Signaling Technology.
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Caspase-3 Activity Assay
Twenty-four hours after H-I, the hippocampal and cortical
tissues from both lesioned and unlesioned hemispheres were
rapidly dissected and Asp-Glu-Val-Asp-(7-amino-4-methylcou-
marin) (DEVD-AMC) cleavage activities were measured as
previously reported [4,36]. Tissue lysates (10 ml) were incubated
Figure 1. 29D7 increases phosphorylation of ERK1/2 and AKT in vivo. P7 rat pups received an icv injection of control IgG or 29D7 (0.3 nmol
in 5 ml PBS) and the cortical tissues were dissected at various time points as indicated. Following preparation of tissue lysates, proteins (30 mg/lane)
were separated by SDS-PAGE and transferred to nitrocellulose membranes. Immunoblotting was performed with antibodies specific to
phosphorylated ERK1/2 (pERK1/2) and total ERK1/2, and phosphorylated AKT (pAKT) and total AKT proteins. Signal intensity was quantified by
densitometry and normalized to corresponding total proteins. Since IgG treatment had no effect on the levels of pERK1/2 and pAKT (P.0.05) for up
to 24 h, all time points of the IgG-treated groups were pooled. Data represent mean 6 SEM (n= 4–5). *P,0.05 compared with the IgG-treated group
by ANOVA followed by Dunnett’s multiple comparison (A–B). C. Levels of phosphorylated ERK1/2 and phosphorylated AKT were compared in male
vs. female mice 2–6 h after icv injection of 29D7, 0.3 nmol (n= 5). N.S.: no significance between male and female mice assessed by t-test (P.0.05).
doi:10.1371/journal.pone.0088962.g001
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with 90 ml of an assay buffer (10 mM HEPES, pH 7.4, 42 mM
KCl, 5 mM MgCl2, 1 mM DTT, and 10% sucrose) containing
30 mM acetyl-DEVD-AMC (Calbiochem, San Diego, CA) and the
enzymatic activities were calculated by kinetic analyses of the
emitted fluorescence (ex: 360 nm; em: 460 nm) measured every
5 min for 30 min. Acetyl-AMC (Calbiochem) was used to obtain a
standard curve and the enzyme activity was presented as
picomoles of AMC per milligram of protein per minute.
Assessment of Brain Damage following Hypoxic-ischemic
Injury
Regional brain loss was determined at 7d or 35d post H-I injury
by calculating the amount of surviving tissue in coronal sections as
previously described [36,40]. Briefly, coronal sections from the
genu of the corpus callosum to the end of the dorsal hippocampus
were stained with cresyl violet. The cross-sectional areas of the
striatum, cortex and hippocampus in each of eight equally spaced
reference planes were photo-scanned and the area of each brain
region was calculated using Adobe Photoshop 6.0. The sections
utilized for quantification in a blinded manner corresponded
approximately to Plates 20, 25, 30, 35, 51, 56, 61 and 66 in the rat
brain atlas of Paxinos and Watson [41].
Immunofluorescent Labeling and Microscopy
Brain tissues were prepared as described previously [36,42,43]
and subjected to immunofluorescent labeling. Briefly, tissue
sections were blocked with Tris-buffered saline containing 1%
bovine serum albumin, 0.2% dry milk and 0.3% Triton X-100 for
30 min and incubated overnight with primary antibodies, followed
by incubation for 2 h with fluorescence-labeled secondary
antibody Alexa-488 or Alexa-568 (Invitrogen, Carlsbad, CA).
After incubation with fluorescence-labeled secondary antibody,
slides were cover-slipped with Vectashield mounting media
(Vector Laboratories, Burlingame, CA) and examined with an
IX71 fluorescence microscope (Olympus, Hamburg, Germany) or
a Zeiss LSM confocal microscope (Zeiss, Oberkochen, Germany).
The following primary antibodies were used: anti-NeuN antibody
conjugated with Alexa 488 (1:100; Millipore, Billerica, MA), and
anti-phospho-ERK1/2 (1:1,000, Cell Signaling Technology).
Tape-removal Test
Sensorimotor dysfunction was assessed by a tape removal test as
described [44,45] in a blind manner. Animals were pre-trained for
3 days before tape-removal test on P28, P35, and P42 (3–5 weeks
after H-I injury). Round sticky labels 12-mm in diameter were
applied to the animal’s forelimbs bilaterally and the latency time
required to remove the labels from forelimbs was recorded. The
maximum time allowed to remove the labels was 60 sec. Three
trials per animal were performed and averaged.
Rotarod Test
We performed a rotarod test to examine motor coordination per
the published protocol [46] with modification. Rats were placed
on the rota-rod treadmill (Rotamex-5, Columbus Instrument,
Columbus, OH), which has an accelerating motor-driven treadmill
and the rotation speed was accelerated from 4 to 40 rpm over
180s. Rats performed two trials with a 15 min inter-trial interval at
postnatal days 28, 29 and 30.
Statistical Analyses
Data were expressed as means 6 SEM. Comparison among
multiple groups were performed with a one-way analysis of
variance (ANOVA) followed by Dunnett’s multiple comparison
method. P value ,0.05 was considered significant.
Results
29D7 Activates ERK1/2 and AKT in Neurons of the
Neonatal Brain
Previous studies have demonstrated that endogenous TrkB
agonists such as BDNF can activate both the ERK1/2 and
PI3K-AKT pathways in responsive cells [47,48]. We first asked
whether the TrkB agonist antibody 29D7 could activate these
pathways in the neonatal brain in vivo. Western blot analyses
revealed that icv injection of 29D7 (0.3 nmol) increased ERK1/
2 phosphorylation and AKT phosphorylation in the cortex
ipsilateral to the icv injection (Fig. 1). Levels of both
phosphorylated ERK1 and phosphorylated ERK2 were signif-
icantly increased by 1 h and lasted up to 24 h after the
injection (Fig. 1A). Similarly, 29D7 significantly increased ATK
phosphorylation at least for up to 24 h. We also found that
increased phosphorylation of ERK1/2 and AKT was noted in
the hemisphere contralateral to the injection, indicating that the
antibody could reach to the entire brain after icv injection (data
not shown). However, icv injection of control IgG (0.3 nmol)
was no effect on the levels of phosphorylated ERK1/2 and
phosphorylated AKT for up to 24 h (P.0.05, data not shown).
Based on the fact that TrkB is expressed in neurons in the brain
[49,50], we hypothesized that activation of ERK1/2 and AKT
by 29D7 may primarily occur in neurons. To address this, brain
tissues were prepared at various timepoints after icv injection of
29D7 and subjected to immunohistochemical analyses. Similarly
to our previous report [36], phosphorylated ERK1/2 (pERK1/
2)-immunoreactivity (2IR) was detectable mostly in neuronal
cell processes in the IgG-treated P7 control rats with no obvious
staining in the cell bodies or nuclei. However, upon icv
injection of 29D7, pERK1/2-IR was greatly increased in all
cellular compartments, including neuronal processes, cell bodies,
and nuclei in neuronal layers of the cortex and the hippocam-
pus (Fig. 2). The prolonged increase in the pERK1/2-IR was
noted in neuronal cell processes through all layers in the cortex
24 h after the injection (data not shown). Double labeling with a
neuron-specific marker, NeuN, revealed that pERK1/2-IR was
localized to neurons (Fig. 2).
29D7 Reduces Acute Apoptotic Brain Damage following
Hypoxic-ischemic Injury
BDNF, one of endogenous agonists for TrkB, has been shown
to be neuroprotective against H-I injury in the developing rat
brains via activation of the ERK1/2 pathways [36,40]. We have
reported that TrkB agonist antibodies elicit the stimulation of
signaling cascades downstream of TrkB activation, resulting in
promotion of neuronal survival and neurite outgrowth in culture
with an equipotent efficacy to BDNF [34]. Therefore, we sought
to further test if 29D7 has neuroprotective effects on neonatal
H-I brain injury in vivo. Consistent with a previous study [39],
H-I insult markedly increased the caspase-3 activity by 24 h (7–
8 fold) in the hippocampus and the cortex of ipsilateral, but not
contralateral, sides of the carotid ligation, as determined by
DEVD-AMC cleavage assay (Fig. 3A, B). ICV administration of
0.3 nmol 29D7 or BDNF potently attenuated the H-I-induced
caspase-3 activation compared to the IgG-treated group (P,
0.05). In subsequent studies employing Western blot analysis, we
also demonstrated that H-I resulted in an increase in the
appearance of caspase-3-cleaved products of p90 poly (ADP-
ribose) polymerase (PARP) as well as p120 a-spectrin 24 h post
Neuroprotective Effects of TrkB Agonist 29D7
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H-I in the hippocampus and the cortex (Fig. 3C,D). Treatments
with 29D7 or BDNF blocked the proteolytic cleavages of both
caspase-3 substrates, indicating their abilities to block caspase-3-
dependent apoptosis following H-I injury (Fig. 3C, D).
Figure 2. 29D7 induces phosphorylation of ERK1/2 in neurons. P7 rats received an icv injection of either IgG or 0.3 nmol of 29D7, and brain
tissues were prepared 2 h after the injection (n=5 per group). Coronally sectioned brain sections were immunofluorescently double-labeled with
anti-phospho-ERK1/2 (pERK1/2) antibody (red) and a neuron-specific marker, NeuN (green), followed by fluorescent microscopy. Note that pERK1/2
signals are co-localized with NeuN staining (indicated by yellow signals) in the cortex ipsilateral to icv injection. Scale bar: 50 mm.
doi:10.1371/journal.pone.0088962.g002
Figure 3. 29D7 blocks caspase-3 activation following H-I brain injury. P7 rats underwent left carotid ligation followed by hypoxic injury for
2.5 h. Animals received an icv administration of IgG, 0.3 nmol of BDNF or 29D7 just prior to hypoxia. Twenty-four hours later, brain tissues were
dissected from the hippocampus (A, C) and the cortex (B, D). A, B. Tissues were lysed and caspase-3 activity was determined by Asp-Glu-Val-Asp-7-
amino-4-methyl-coumarin (DEVD-AMC) cleavage assay. Data indicate mean 6 SEM. * p,0.05 compared with contralateral hemisphere; # p,0.05
compared with a IgG-treated ipsilateral hemisphere, as analyzed by ANOVA followed by Dunnett’s comparison method. C, D. Tissue proteins (30 mg/
lane) were separated by SDS-PAGE and subjected to immunoblotting with antibodies specific to poly(ADP-ribose) polymerase (PARP), a-spectrin, and
b-actin. Data shown are representative of 6 independent experiments.
doi:10.1371/journal.pone.0088962.g003
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29D7 Results in the Long-term Neuroprotection against
H-I Injury
We explored long-term neuroprotective effects of 29D7 on H-I
brain injury. Neonatal rats underwent H-I brain injury at P7 and
hemispheric tissue loss was assessed 7 days after H-I. Consistent
with previous reports [36,39], an unilateral carotid ligation
followed by exposure to hypoxia for 2.5 h resulted in brain tissue
loss by 40–60% in the striatum, hippocampus, and cortex in the
IgG-treated group compared to the unlesioned hemisphere
(Fig. 4A–D). ICV injection of 29D7 (0.1 or 0.3 nmol) significantly
reduced the brain tissue loss at 1 week in all brain regions studies
in a dose-dependent fashion as compared to the IgG-treated group
(Fig. 4A–B). This robust neuroprotective effect of 29D7 was also
observed when the tissue loss was analyzed 5 weeks post H-I
(Fig. 4C). To examine the possibility that neuroprotective effect of
29D7 was attributed to hypothermia which is shown to attenuate
H-I brain injury [51,52], body temperatures were monitored
(Fig. 5). We found the body temperature of rats treated with 29D7
did not differ from those treated with control IgG or sham surgery
for up to 7 days after H-I injury (P.0.05).
29D7 Prevents Long-term Neurological Dysfunction
following H-I Brain Injury
We next sought to explore if 29D7-mediated neuroprotection
was associated with long-term behavioral improvements by
employing the sticky tape-removal method, a widely used test of
somatosensory function in rodents [44,45]. As shown in Fig. 6A,
treatment with 29D7 significantly improved neurological dysfunc-
tions as compared to the IgG-treated group (P,0.05) when
assessed at P28–42 (3, 4, and 5 weeks after injury). Histological
analysis of the brain tissue confirmed persistent neuroprotection by
29D7 at P42 (Fig. 4C). Performances in the tape-removal test
significantly correlated with the cortical tissue loss (Fig. 6B,
R
2
= 0.629, P,0.001). We performed a rotarod test to determine
the effects of 29D7 on motor coordination and balance 3 weeks
after H-I injury. Though there was a trend towards worse
performance in both H-I:IgG and H-I;29D7 groups compared
with sham-operated group, 29D7 did not appear to improve
rotarod performance (P.0.05 bewteen H-I:IgG vs. H-I:29D7).
Discussion
Our study here presents evidence that 1) the TrkB-selective
agonist antibody 29D7 effectively activates the TrkB signaling
cascades in vivo, 2) significantly inhibits neuronal cell loss, and 3)
elicits long-term neuroanatomical and behavioral benefits against
H-I injury. Cell survival-promoting effects of neurotrophins, in
particular BDNF, are elicited by activation of different intracel-
lular signaling cascades including the phosphatidylinositol 3-kinase
(PI3-K) and AKT, and the extracellular signal-related kinase1/2
(ERK1/2) pathways [48,53,54]. We found that icv administration
of 29D7 markedly increased levels of phosphorylation of both
ERK1/2 and AKT proteins in the normal mouse brain. Double
immunolabeling studies confirmed that ERK1/2 phosphorylation
occurred in the neuronal population. Interestingly, 29D7-induced
ERK1/2 phosphorylation in the cortex was slower in initiation
compared to that in the hippocampus (data not shown), while the
activity was long lasting at least up to 24 h. This regional
difference might be attributed in part to temporal differences in
access to the antibody between two tissues related to penetration
distances. Differential kinetics of ERK1/2 activation has also been
reported; however, a continuous exposure to BDNF over 2–6 h
was required for a persistent phosphorylation of ERK1/2 for
cortical neurons in culture [55,56], while BDNF elicited a rapid
and transient activation of ERK1/2 in hippocampal slices [57]. In
fact, ERK1/2 activation in the hippocampus was previously
shown to be more robust compared to other brain regions
including the cortex, suggesting region-specific regulations of
ERK1/2 activity in the brain [58].
Our results strongly demonstrated that pretreatment with 29D7
provided neuroprotection against H-I brain injury in P7 rats, as
assessed by acute caspase-3 activation 24 h post-H-I as well as by
long-term brain tissue loss 1–5 weeks following H-I insult (Figs. 3
and 4). Previous reports demonstrate that H-I insult to the
developing brain results in mainly apoptotic cell death, accompa-
nying typical hallmarks such as DNA laddering, nuclear conden-
Figure 4. 29D7 exerts long-term neuroprotection against H-I
brain injury. P7 rats underwent left carotid ligation and hypoxia for
2.5 h. Animals received an icv administration of IgG or 29D7 (0.1 nmol
or 0.3 nmol) prior to hypoxia. Seven days later, brains were removed,
coronally sectioned, and stained with cresyl violet. A. Representative
photographs illustrating hemispheric tissue loss after H-I injury. B. Area
tissue loss from the striatum, hippocampus, and cortex was determined
by comparing the area of surviving tissue with unlesioned (right)
hemisphere. Data indicate mean 6 SEM. *P,0.05 compared to the IgG-
treated group. C. Animals used in behavioral studies in Fig. 5 were
subjected to tissue loss analysis at P42. *P,0.05 compared to the sham-
operated group; #P,0.05 compared to a control IgG-treated, H-I
group.
doi:10.1371/journal.pone.0088962.g004
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sation and delayed caspase-3 activation [4,40]. Han and Holtzman
found that icv administration of BDNF markedly protected the
neonatal brain following H-I [36]. This BDNF’s neuroprotective
action was blocked by pretreatment with an ERK1/2 inhibitor,
U0126, but not with an PI3-K inhibitor, wortmannin [36],
suggesting a central role of the ERK1/2 pathway in mediating the
neuroprotecive effect of BDNF on H-I brain injury in developing
brain. The notion that 29D7 robustly induces phosphorylation of
ERK1/2 in vivo (Figs. 1 and 2) as well as in vitro [34] supports the
idea that 29D7-mediated neuroprotection would be, at least in
part, mediated via the ERK1/2-dependent mechanism. Further
insights into the ERK1/2 downstream mediators that are required
for protection against injury in vivo seem warranted to attempt to
elucidate the molecular mechanism underlying neuroprotective
action of 29D7 [59,60].
In the present study, we found that the neuronal rescue was
closely linked to a long-term improvement of somatosensory
function (Fig. 6) as assessed by tape removal test, one of the most
sensitive testes for detecting sensorimotor deficits [61] [44,45]. For
example, Yager et al. have compared various neurobehavioral
tests following ischemic brain damage to establish correlations
between functional performance and morphologic damage levels
in rats of various age groups [46]. Interestingly, among the battery
of tests conducted in their study, including rotarod, foot-fault,
open-field, inclined screen and postural reflex tests, a tape-removal
test was the only one that showed effects of an age, treatment and
a recovery duration, suggesting that this tape-removal test provides
the most tractable measure correlating to the extent of cortical
damages following ischemic stroke [46]. In that study, however,
the authors did not observe a group difference between control
and ischemic animals by rotarod test probably due to technical
problems (for examples, some mice were motivated to jump off
from the treadmill during tests). Consistent with this report, we
also failed to find a correlation between the extent of morpholog-
ical protection by 29D7 and an increased retention on the
treadmill in the rotarod test (Fig. 6C). Many lines of evidence
demonstrate that post-injury hypothermia elicits neuroprotection
after ischemic stroke in adult rodents [62,63,64] and after hypoxia-
ischemia in neonatal animals [65,66]. We found that 29D7 did not
affect the body temperature up to 7 days after H-I in P7 rats
(Fig. 5), suggesting hypothermia does not appear to account for
29D7’s neuroprotective action.
We found that icv injection of 29D7 increased the TrkB
phosphorylation to a same extent in both male and female rats
(Fig. 1C). A recent study showed that TrkB activation by a
flavonoid analog 7,8 dihydroxyflavone afforded significant neuro-
protection in female, but not in male, when hippocampal neuronal
damage was assessed 72 h following H-I in P9 neonatal mice [67].
The authors reported that 7,8 dihydroxyflavone increased the
TrkB phosphorylation to a greater extent in female mice than in
Figure 5. 29D7 does not affect body temperature. P7 rats
underwent left common carotid ligation or sham surgery, followed by
hypoxia for 2.5 h. The animals subjected to H-I injury were treated with
an icv administration of control IgG or 29D7 immediately before
hypoxia. Body temperature of the pups was measured at various time
points indicated using a digital infrared thermometer. Data indicate
mean 6 SEM. No significance between groups assessed by one way
ANOVA (P.0.05).
doi:10.1371/journal.pone.0088962.g005
Figure 6. 29D7 improves functional outcome following H-I injury. P7 rats underwent sham operation (Sham) or H-I brain injury by left carotid
ligation and subsequent exposure to hypoxia for 2.5 h. H-I animals received an icv administration of 0.3 nmol control IgG or 29D7, 0.3 nmol prior to
hypoxia. A. Sensorimotor function was assessed by a tape-removal test at P28, P35, and P42. Data represent mean 6 SEM. *P,0.05 compared with
sham; #P,0.05 compared with IgG treated group, analyzed by ANOVA and Dunnett’s multiple comparison test. B. Correlation between % cortical
tissue loss and functional performances. Functional performance of individual animals in A was plotted against the percentage of cortical tissue loss,
as exemplified in Figure 4C. C. Motor coordination function was assessed by a rotarod test 3 weeks after H-I injury. P.0.05 between groups.
doi:10.1371/journal.pone.0088962.g006
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male mice following H-I, which may account for gender-depend
neuroprotective action of this compound. Interestingly, H-I insult
alone also increased the TrkB phosphorylation almost equally in
both genders [67]. In addition to TrkB, 7,8 dihydroxyflavone is
shown to have a variety of biochemical properties, including
antioxidant activity [68], downregulation of cyclin E [69], and
antiinflammation via inhibiting NF-kB activation and MAPK
activation [69], which may also contribute, at least in part, to
neuroprotective action of this compound. The TrkB-selective
agonist 29D7, therefore, would provide as an indispensible tool for
further studies to explore wether TrkB activation leads to
neuroprotection preferentially in female animals following H-I.
In summary, the present study shows that the TrkB agonist
29D7 provides long-lasting neuroprotection against neonatal H-I
injury in vivo. Additional studies with post treatment paradigms
should further be able to shed lights on the potential clinical utility
of 29D7 in the treatment of H-I brain injury in developing brain.
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